

Wilms' Tumor Therapeutic and Drug Pipeline Review H2

Global Wilms' Tumor Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, January 11, 2017
/EINPresswire.com/ -- Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016

GET SAMPLE REPORT @
<https://www.wiseguyreports.com/sample-request/867078-wilms-tumor-nephroblastoma-pipeline-review-h2-2016>

Summary

Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym. Wilms' tumor is a rare kidney cancer that primarily affects children. Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com
☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <https://twitter.com/WiseGuyReports>
📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Wilms' Tumor (Nephroblastoma) Overview 6

Therapeutics Development 7

Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview 7

Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis 8

Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies 9

Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes 10

Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Wilms' Tumor (Nephroblastoma) - Products under Development by Companies 13

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/867078-wilms-tumor-nephroblastoma-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.